

## IPA to host 5th India Pharmaceutical Forum

17 February 2020 | News

**The conference will focus on 'Patient Centricity and Integrated Quality Management' Dr P D Vaghela, Secretary, Department of Pharmaceuticals, Government of India to deliver the Keynote Address and release of IPA guidelines on Market Complaints An exclusive CEO Panel on Patient Centricity and Integrated Quality Management**



Patient Centricity and Integrated Quality Management is the theme for this year's India Pharmaceutical Forum, organized by the Indian Pharmaceutical Alliance (IPA) to be held in Mumbai from February 27-28. Now in its 5<sup>th</sup> edition, the event will bring manufacturers, regulators, academia and other relevant stakeholders together facilitate discussions resulting in meaningful and actionable outcomes. Dr P D Vaghela, Secretary, Department of Pharmaceuticals, Government of India will deliver the Keynote Address and release the IPA guidelines on Market Complaints.

An update on the Center for Drug Evaluation and Regulation (CDER) and recent Cross-Contamination Case Studies will be presented by Dr. Francis Godwin, Director, Office of Manufacturing Quality (OMQ), Office of Compliance (OC), USFDA. Dr. Samantha Atkinson, Director of Inspection, Enforcement and Standards (IE & S), Medicines and Healthcare Products Regulatory Agency (MHRA), will helm a session on Culture Transformation Best Practices, along with Ms Susan Schniepp, Chair-elect, Parenteral Drug Association (PDA) and Mr Johnny Mikell, President, Global Quality, Lupin.

"We are in the midst of a patient-centred care revolution in healthcare. The 5<sup>th</sup> India Pharmaceutical Forum provides an apt opportunity for industry, regulators and other players to engage in discussions on patient centricity and quality management systems. At the same time, the forum will provide a platform to pharma and healthcare professionals to reflect on the journey so far in terms of Quality" said Mr Sudarshan Jain, Secretary-General, IPA.

"India is the pharmacy of the world and accounts of approximately 20 per cent of market share globally in volume terms and IPA is committed to providing quality medicines to its consumers across the globe. For us patient safety and health is paramount," he added.

The 5th India Pharmaceutical Forum has ten sessions addressing various aspects of drug manufacturing such as Quality, Capability Building, Affordability and Patient-Centric Approach among other topics. The Forum will culminate with a Panel Discussion on Patient Centricity and Integrated Quality Management which will bring together the CEOs of top Indian Pharma companies such as Lupin, Dr. Reddy's, Sun Pharma, Cadila and Cipla among others on one platform to discuss a way forward for the Industry.